Editors' note: Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In “Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial,” Benussi et al. exposed 20 patients with neurodegenerative ataxia to cerebello-spinal transcranial direct current stimulation (tDCS) and sham stimulation and found that tDCS resulted in significant improvement in performance, motor cortex excitability, and cerebellar brain inhibition. Matsugi speculated that Benussi et al.'s findings demonstrate that spinal-cerebellar functional connectivity is retained in spinocerebellar ataxia and improved with tDCS. He noted that further study into cerebellar brain facilitation and inhibition and spinal direct current stimulation in this patient population are needed. Benussi et al. replied that they believe simultaneous spinal and cerebellar tDCS synergistically improves cerebellar function and spasticity, and agreed that further studies on the distinct and combined effects of cerebellar and spinal tDCS are needed, as stimulation may benefit this patient population for whom no drugs are available.
In “Severe hyperhomocysteinemia manifesting as moyamoya vasculopathy and Henoch-Schonlein purpura,” Cho et al. described a 37-year-old woman with a history of Henoch-Schonlein purpura with leukocytoclastic vasculitis and immune mesangiopathic glomerulonephritis who presented with recurrent ischemic infarcts and was found to have hyperhomocysteinemia due to homozygous cystathionine β-synthase (CBS), then developed moyamoya vasculopathy requiring a direct bypass on the left and an encephalo-duro-arterio-synangiosis procedure on the right. The authors suggested that the cerebral, skin, and renal changes are all the result of CBS deficiency. In review of this case, Drs. Gaillard and Arquizan postulate that the underlying mechanism was likely a systemic vasculitis with CNS involvement and question whether (1) inflammatory markers, autoantibodies, and serologies were checked in serum or CSF, (2) a brain biopsy was obtained, or (3) a trial of steroids or immunosuppressants was given. Cho et al. respond that (1) serial cerebral angiograms showed progressive intracranial stenosis consistent with moyamoya vasculopathy, not with vasculitis, and (2) CSF showed no pleocytosis, and inflammatory and infectious tests were negative. They note that there was no recurrence of skin or renal events despite the absence of systemic therapy, making the diagnosis of secondary CNS vasculitis unlikely. While both Cho et al. and Drs. Gaillard and Arquizan agree that the high-resolution MRI was suggestive of vasculitis, Cho et al. believe it is consistent with a moyamoya-like vasculopathy and that this case represents a new phenotype of CBS deficiency.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Alert Me
Recommended articles
-
Disputes & Debates: Editors' Choice
Author response: Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trialAlberto Benussi, Barbara Borroni et al.Neurology, June 03, 2019 -
Disputes & Debates: Editors' Choice
Reader response: Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trialAkiyoshi Matsugi et al.Neurology, June 03, 2019 -
Disputes & Debates: Editors' Choice
Editors' note: Severe hyperhomocysteinemia manifesting as moyamoya vasculopathy and Henoch-Schonlein purpuraAriane Lewis, Steven Galetta et al.Neurology, June 03, 2019 -
Disputes & Debates: Editors' Choice
Author response: Severe hyperhomocysteinemia manifesting as moyamoya vasculopathy and Henoch-Schonlein purpuraSung-Min Cho, Rodica Di Lorenzo, Jonathan L. Myles et al.Neurology, June 03, 2019